|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021079,
umls-concept:C0021080,
umls-concept:C0022671,
umls-concept:C0038317,
umls-concept:C0040808,
umls-concept:C0085149,
umls-concept:C0205225,
umls-concept:C0205263,
umls-concept:C0209368,
umls-concept:C0376387,
umls-concept:C0663182
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-4-19
|
|
pubmed:abstractText |
Recent reports have demonstrated the efficacy of interleukin-2-receptor blockers in lowering the incidence of early acute rejection in cyclosporine-treated kidney recipients when compared to patients not induced with an antibody product. The addition of daclizumab to a tacrolimus-mycophenolate mofetil-based immunosuppressive protocol was tested to evaluate whether there might be an additional reduction of the risk of rejection after renal transplantation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Methylprednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Muromonab-CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Mycophenolic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus,
http://linkedlifedata.com/resource/pubmed/chemical/daclizumab,
http://linkedlifedata.com/resource/pubmed/chemical/mycophenolate mofetil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1100-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11965039-Adolescent,
pubmed-meshheading:11965039-Adult,
pubmed-meshheading:11965039-Aged,
pubmed-meshheading:11965039-Antibodies, Monoclonal,
pubmed-meshheading:11965039-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:11965039-Child,
pubmed-meshheading:11965039-Child, Preschool,
pubmed-meshheading:11965039-Diabetes Mellitus,
pubmed-meshheading:11965039-Graft Survival,
pubmed-meshheading:11965039-Humans,
pubmed-meshheading:11965039-Hyperlipidemias,
pubmed-meshheading:11965039-Immunoglobulin G,
pubmed-meshheading:11965039-Immunosuppressive Agents,
pubmed-meshheading:11965039-Infant,
pubmed-meshheading:11965039-Kidney Transplantation,
pubmed-meshheading:11965039-Methylprednisolone,
pubmed-meshheading:11965039-Middle Aged,
pubmed-meshheading:11965039-Muromonab-CD3,
pubmed-meshheading:11965039-Mycophenolic Acid,
pubmed-meshheading:11965039-Prospective Studies,
pubmed-meshheading:11965039-Tacrolimus
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
|
|
pubmed:affiliation |
Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Miami, FL 33101, USA.
|
|
pubmed:publicationType |
Journal Article
|
